148 patients were screened (Fig. 1), 6 were deemed ineligible for tisagenlecleucel due to active graft-versus-host disease (n = 3), CD19 negative disease (2), and lymphopenia precluding leukapheresis (1). This evidence concerns the gene CD19 and graft versus host disease.